A number of anti-diabetic preparations, such as an inhibitor of dipeptidyl peptidase 4 (DPP-4) Sitagliptin and sodium-glucose co-transporter 2 (SGLT2) inhibitor Dapagliflozin, have been shown to stimulate the anti-inflammatory polarization of macrophages, and thus prevent the formation of atherosclerotic lesions [43,44]. Here, DPP4 is linked to Atherosclerotic lesion.